Morgan Stanley's Growth Initiatives Amid Cyclical Peaks: A Critical Look

What happened

Morgan Stanley has announced strategic collaborations, including the EquityZen buyout and a Zerohash crypto tie-up, aiming to broaden its markets and boost its wealth platform. However, the DeepValue report indicates that MS is at a cyclical high, with 2025 showing record revenues but likely unsustainable returns on tangible common equity (ROTCE) and wealth management margins. The stock trades at ~18-19x EPS and ~2.7x book value, embedding expectations of continued high performance that may not hold as investment banking and trading revenues normalize. These new initiatives are part of MS's broader growth strategy, but they face integration challenges and may not significantly offset impending headwinds from credit normalization and regulatory pressures. Ultimately, while the collaborations aim to drive long-term growth, the current valuation leaves little margin for error and exposes investors to downside risks if earnings revert to more typical levels.

Implication

The collaborations with EquityZen and Zerohash may provide incremental growth opportunities, but they are relatively small compared to MS's core businesses and come with execution risks. Given the base case implied value of $180, below the current price of $191.90, there is limited upside and significant downside to $150 in a bear scenario. Wealth management margins, a key valuation support, are projected to compress from ~30% towards the high-20s, undermining one of MS's main earnings anchors. Credit normalization and potential regulatory changes could further pressure returns, increasing the risk of multiple compression. Therefore, investors should consider trimming positions or awaiting a more attractive entry point, as the risk-reward profile is unfavorable at current levels.

Thesis delta

The new strategic collaborations do not materially change the thesis that MS is overvalued due to cyclical peaks in earnings. They represent management's effort to sustain growth, but these initiatives are insufficient to counteract the expected normalization in investment banking and wealth management margins. Thus, the sell recommendation remains, with added emphasis on the timing and impact of these growth efforts.